Compare Arko Corp. (ARKO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs State Street SPDR S&P Biotech ETF — how do they compare? Arko Corp. trades at $4.51 (market cap $493.06M), while State Street SPDR S&P Biotech ETF trades at $158.97. The key difference: Arko Corp. pays a 2.73% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Arko Corp. nearer its low. Which is the better fit depends on your goals.
| ARKO | XBI | |
|---|---|---|
Market Cap | $493.06M | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $8.64 | $164.28 |
52-Week Low | $3.82 | $86.92 |
Enterprise Value | $2.67B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.51, down 4.04% amid a bearish technical trend. The stock shows mixed fundamentals: revenue declined to $7.64B in 2025, but net income improved to $22.74M. Recent Q2 2026 earnings missed estimates, with EPS of $0.04 versus $0.15 expected. The company maintains a dividend, paying $0.03 per share semi-annually, and holds a low P/S ratio of 0.06, though the P/E is elevated at 54.94. Analyst sentiment is neutral with all three covering analysts rating it Hold.
Outlook remains cautious due to declining revenue trends and competitive pressures in the convenience store sector. The stock's low price near recent support levels may attract value investors, but risks include volatile fuel margins and high debt. Institutional interest is present, with Dimensional Fund Advisors increasing its stake by 7.3% in Q2 2026.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
